Table 2.
Patient characteristics and demographics
| All CSU (N = 582) |
CSU-only (N = 370) |
CSU + CIndU (N = 212) |
|
|---|---|---|---|
| Age (years), mean (SD) | 42.2 (11.9) | 43.2 (12.1) | 40.4 (11.2) |
| [95% CI] | [41.2–43.2] | [42.0–44.4] | [38.9–41.9] |
| Gender, N (%) | |||
| Female | 362 (62%) | 225 (61%) | 137 (65%) |
| Male | 220 (38%) | 145 (39%) | 75 (35%) |
| Years since onset, mean (SD) | 9.2 (10.3) | 8.1 (9.8) | 11.1 (10.7) |
| Years since CU diagnosis, mean (SD) | 7.1 (8.5) | 6.2 (7.9) | 8.7 (9.4) |
| No. of years between onset and diagnosis, mean (SD) | 2.0 (5.4) | 1.8 (5.3) | 2.3 (5.6) |
| Number of comorbidities, mean (SD) | 2.4 (2.7) | 1.9 (2.1) | 3.3 (3.3) |
| Adequate control (UCT 12–16), N (%) | 114 (20%) | 89 (24%) | 25 (12%) |
| Inadequate control (UCT < 12), N (%) | 468 (80%) | 281 (76%) | 187 (88%) |
| Current treatments, mean (SD) | 2.9 (2.6) | 2.4 (2.1) | 3.7 (3.1) |
| Any antihistamines, N (%) | 460 (79%) | 272 (74%) | 188 (89%) |
| Any steroids, N (%) | 290 (50%) | 173 (47%) | 117 (55%) |
| Any biologic, N (%) | 193 (33%) | 106 (29%) | 87 (41%) |
| Exclusively on antihistamines, N (%) | 138 (24%) | 87 (24%) | 51 (24%) |
| Exclusively on steroids, N (%) | 45 (8%) | 37 (10%) | 8 (4%) |
| Exclusively on biologics, N (%) | 18 (3%) | 14 (4%) | 4 (2%) |
| On mixed treatment, N (%) | 381 (65%) | 232 (63%) | 149 (70%) |
| Country, N (%) | |||
| USA | 152 (26%) | 105 (28%) | 47 (22%) |
| Canada | 73 (13%) | 52 (14%) | 21 (9.9%) |
| UK | 87 (15%) | 45 (12%) | 42 (20%) |
| Germany | 79 (14%) | 44 (12%) | 35 (17%) |
| France | 86 (15%) | 53 (14%) | 33 (16%) |
| Italy | 64 (11%) | 41 (11%) | 23 (11%) |
| Japan | 41 (7%) | 30 (8%) | 11 (5%) |
Patients using any combination of medications, such as antihistamines, steroids and biologics, were categorized as being on mixed treatment
CI confidence interval; CIndU chronic inducible urticaria; CSU chronic spontaneous urticaria; CU chronic urticaria; SD standard deviation; UCT Urticaria Control Test